Author:
Zhai Qihui “Jim”,Deng Fang-Ming
Publisher
Springer International Publishing
Reference47 articles.
1. Moch H, Humphrey PA, Ulbright TM, Reuter VE. WHO classification of tumors of the urinary system and male genital organs. 4th ed. Lyon: IARC Press; 2016.
2. McKenney JK, Desai S, Cohen C, Amin MB. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium. An analysis of cytokeratin 20, P53, and CD44 antigens. Am J Surg Pathol. 2001;25(8):1074–8.
3. Mallofre C, Castillo M, Morente V, Sole M. Immunohistochemical expression of CK20, P53, and Ki-67 as objective markers of urothelial dysplasia. Mod Pathol. 2003;16:187–91.
4. Kunju LP, Lee CT, Montie J, Shah RB. Utility of cytokeratin 20 and Ki-67 as objective markers of urothelial dysplasia. Pathol Int. 2005;55(5):248–54.
5. Alston ELJ, Zynger DL. Does the addition of AMACR to CK20 help to diagnose challenging cases of urothelial carcinoma in situ? Diagn Pathol. 2019;14(1):91.